The dominant narrative – reinforced by clinical guidelines, public campaigns, and a strained NHS – presents stimulants like Methylphenidate and amphetamines as the cornerstone of evidence-based ADHD care. Yet when we turn to the Cochrane Collaboration’s systematic reviews, regarded as the gold standard in impartial synthesis, a more cautious and sobering assessment emerges. This is not about rejecting stimulant psychotropics outright. It is about insisting on intellectual honesty.
The Quality of Evidence: Very Low, Consistently
Cochrane applies the GRADE framework with rigour. For both children and adults, the quality of evidence supporting stimulant efficacy is graded very low.1,2 This is not a marginal concern; it is a foundational limitation. The reasons are structural:
- High risk of bias – many trials are industry-funded, with inadequate blinding or selective reporting.
- Short duration – most studies last 2–13 weeks, offering no insight into lifelong prescribing.
- Inconsistency and imprecision – effect sizes vary widely, confidence intervals often straddle clinical relevance.
- Indirectness – participants are highly selected, excluding common comorbidities and real-world complexity.
This is not robust science. It is provisional data, heavily caveated.
Efficacy: Statistically Detectable, Clinically Uncertain
| Population | Symptom Reduction (SMD) | Functional Outcomes |
|---|---|---|
| Children & Adolescents | −0.20 to −0.49 (small) | No reliable improvement in academic achievement, peer relationships, or long-term adjustment1 |
| Adults | −0.37 (small to moderate) | No change in employment stability, workdays missed, or quality of life2 |
These are not transformative effects. They are modest shifts on rating scales – often completed by observers aware of treatment status. Whether they translate into meaningful life improvement remains unknown. Cochrane is clear: we lack evidence of long-term benefit.1,2
Harms: Frequent, Minimised, Poorly Tracked
Adverse effects are not rare exceptions. They are the norm:
- Over 50% of children on stimulants experience at least one adverse event.1,3
- Relative risk of any adverse event: 1.44 (95% CI 1.18–1.76).
- Decreased appetite (RR 3.49), insomnia (RR 3.34), abdominal pain, anxiety, and emotional flattening are routine.1,3
But this figure may understate the reality. A complementary Cochrane review of 73 non-randomised studies involving over 12,000 children and adolescents found that more than half (51.3%) experienced one or more non-serious adverse events, such as decreased appetite, sleep difficulties, and abdominal pain.3 This real-world evidence highlights how harms persist beyond the controlled settings of short-term RCTs, where reporting is often incomplete or selective.
These are not trivial. They disrupt sleep, growth, mood, and family life – yet are frequently reframed as “temporary” or “manageable”. Serious harms? The 2018 Cochrane review of non-randomised studies finds that about 1 in 100 patients treated with Methylphenidate seemed to suffer a serious harmful event, including death, cardiac problems, and psychotic disorders. Although the Cochrane authors assess their certainty in the evidence as low, they note that studies funded by pharmaceutical companies reported a much lower proportion of both serious and non-serious adverse events, confirming previous studies and systematic reviews on industry bias. Long-term safety data are effectively absent.1,2,3 with the non-randomized review underscoring the urgent need for better monitoring in everyday practice.3
Adults: A Market Expansion Built on Fragile Ground
The 2022 Cochrane review of extended-release Methylphenidate in adults (16 trials, ~3,800 participants) reaches the same conclusion: very low-quality evidence.2 A prior review of immediate-release formulations was withdrawn in 2016 due to pervasive methodological flaws. Despite this, private clinics proliferate, fuelled by NHS waiting times stretching to eight years in some regions. Demand is real. But so is the risk of over-medicalisation without adequate evidential warrant.
The “Under-Treatment” Narrative Re-Examined
Official reports lament “unmet need” and “under-diagnosis”. Yet Cochrane’s position is unambiguous:
“It is uncertain whether Methylphenidate improves ADHD symptoms in children and adolescents because the certainty of the evidence is very low… We do not know the balance between benefits and harms.”1
The same applies to adults. This is not a mandate for widespread prescribing. It is a call for restraint.
An Evidence-Respecting Conclusion
Stimulant psychotropics are pharmacological tools, not cures. They produce detectable but limited short-term symptom changes, at the cost of frequent adverse effects, within a body of research Cochrane deems very low quality.1,2 We are not “treating” a clearly defined brain disorder with proven, safe, long-term interventions. We are managing behavioural and emotional distress with drugs of uncertain net benefit – often in children, often for decades. Until we have independent, long-term, real-world outcome studies? The precautionary principle should guide practice. Not the prescription pad. Cochrane does not oppose stimulant psychotropics. It demands full disclosure and truth in advertising. And the truth is: we do not yet know enough.
- Storebø OJ, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews 2023, Issue 3.
- López-López JA, et al. Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews 2022, Issue 2.
- Storebø OJ, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomised studies. Cochrane Database of Systematic Reviews 2018, Issue 5.
